Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 41Stomach Neoplasms 22Esophageal Neoplasms 20Esophageal Squamous Cell Carcinoma 19Colorectal Neoplasms 12Pancreatic Neoplasms 9Liver Neoplasms 6Cholangiocarcinoma 6Biliary Tract Neoplasms 5Advanced Gastric Cancer 5Locally Advanced Gastric Cancer 4Rectal Neoplasms 3Neoplasms 2Neoplasm Metastasis 2Metastatic Gastric Adenocarcinoma 2Locally Advanced Rectal Cancer 2Liver Diseases 2Gastrointestinal Neoplasms 2Esophageal Diseases 2Digestive System Neoplasms 2Colonic Neoplasms 2Advanced Gastric Adenocarcinoma 2Unresectable Gallbladder Cancer 1Turcot syndrome 1Stomach Diseases 1Stage IV Gastric Cancer With Metastasis 1Second Line Treatment of Gastric Cancer 1SHR-1210 1Recurrence 1Rectal Cancer Patients 1

Interventions

Oxaliplatin 2Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1Surgical Procedures, Operative 1S 1 (combination) 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Borderline Resectable Pancreatic Cancer × camrelizumab × Gastrointestinal × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡